Skip to content
Inciteful Med

The Biology and Genetic Subtypes of CMT

Last updated:

Charcot-Marie-Tooth (CMT) disease is caused by genetic mutations that damage peripheral nerves. CMT is grouped into subtypes based on whether the nerve's core (axonal) or its insulation (demyelinating) is affected. Identifying your specific mutation helps determine prognosis and family risk.

Key Takeaways

  • • CMT damages peripheral nerves by affecting either the nerve core (axon) or its protective insulation (myelin).
  • • Nerve Conduction Velocity (NCV) tests help doctors determine if you have demyelinating (Type 1) or axonal (Type 2) CMT.
  • • CMT1A is the most common genetic subtype, accounting for roughly 60% of all cases.
  • • CMT is highly hereditary and can be passed down through dominant, recessive, or X-linked genetic patterns.
  • • Identifying your specific genetic mutation is the gold standard of diagnosis and helps tailor future treatments.

To understand Charcot-Marie-Tooth (CMT), it helps to look at the biology of your nerves. Your peripheral nerves—the ones that travel to your arms and legs—act much like electrical cables. They have two main parts that can be affected by the genetic mutations of CMT [1][2].

The Wire Analogy

Imagine a standard electrical wire:

  • The Axon (The Copper Wire): This is the core of the nerve that carries the electrical signal [2].
  • The Myelin (The Rubber Insulation): This is the protective coating that keeps the signal from leaking out and helps it travel fast [2][3].

The Two Main Biological Categories

Doctors use Nerve Conduction Velocity (NCV) tests to measure how fast and how strong your nerve signals are. This helps them determine which part of the “cable” is damaged [1][4].

  • CMT Type 1 (Demyelinating): This is an “insulation problem.” The myelin is damaged or missing, causing the signal to slow down significantly [2][1].
  • CMT Type 2 (Axonal): This is a “wire problem.” The core of the nerve (the axon) is damaged. The signal speed might be normal, but the signal itself is too weak to reach the muscle effectively [2][1].

There are also Intermediate forms, where both the insulation and the wire are affected, and CMT Type 4, which refers to rare forms that are inherited in a “recessive” pattern [5][6].

Common Genetic Subtypes

While there are over 100 to 140 different genes that can cause CMT, a few specific mutations account for the majority of cases [7][8].

Subtype Gene Mutation Frequency Key Features
CMT1A PMP22 (duplication) ~60% of cases Demyelinating; most common form; usually slow progression [9][2].
CMTX1 GJB1 (Connexin 32) 2nd most common X-linked; can cause transient “stroke-like” episodes in rare cases [10][2].
CMT2A MFN2 Most common CMT2 Axonal; often more severe; can involve the optic nerve (vision) [11][12].
CMT1B MPZ Common CMT1 Demyelinating; can range from very mild to severe infantile onset [2][13].

How CMT is Inherited

Understanding how CMT is passed down can help you understand the risk to other family members.

  • Autosomal Dominant: You only need one copy of the mutated gene (from one parent) to have the condition. This is the most common pattern, seen in CMT1A [14][15]. There is a 50% chance of passing it to a child per pregnancy [14].
  • Autosomal Recessive: You must inherit two copies of the mutated gene (one from each parent). The parents are usually “carriers” and do not show symptoms [16][17]. There is a 25% chance of passing it to a child per pregnancy.
  • X-Linked: The mutation is on the X chromosome. This often affects males more severely than females, as males only have one X chromosome [18][19].

Because CMT has strong hereditary patterns, working with a Genetic Counselor is a crucial next step for newly diagnosed patients. They can help you navigate family planning and discuss whether relatives should be tested [20].

Identifying your specific genetic subtype is the “gold standard” of diagnosis [20]. It allows your care team to give you a more accurate prognosis and ensures you are ready for future treatments tailored to your specific mutation [7][21].

Frequently Asked Questions

What is the difference between CMT Type 1 and CMT Type 2?
CMT Type 1 is a demyelinating condition where the protective insulation around the nerve is damaged, causing signals to slow down. CMT Type 2 is an axonal condition where the core wire of the nerve is damaged, resulting in a signal that is too weak to effectively reach the muscle.
What is the most common genetic subtype of CMT?
The most common subtype is CMT1A, which accounts for about 60% of cases. It is a demyelinating form of the disease caused by a duplication of the PMP22 gene and usually has a slow progression.
How is Charcot-Marie-Tooth disease inherited?
CMT can be inherited in several ways, with the most common being autosomal dominant, where you only need one copy of the mutated gene from one parent. It can also be passed down through autosomal recessive or X-linked inheritance patterns.
Why should I see a genetic counselor for CMT?
A genetic counselor can help you understand your specific CMT mutation, navigate family planning, and discuss the risks of passing the condition on to your children. They can also advise on whether other relatives should be tested.

Questions for Your Doctor

  • • Based on my genetic test results, what is my specific CMT subtype (e.g., CMT1A, CMT2A, CMTX1)?
  • • Is my condition 'demyelinating' or 'axonal,' and what does that mean for how the nerve signals are being disrupted?
  • • What is the inheritance pattern for my specific mutation, and what are the chances of passing it on to my children?
  • • Can you refer me to a Genetic Counselor to help my family navigate testing?

Questions for You

  • • Do I have a copy of my genetic testing report and my Nerve Conduction Velocity (NCV) results to share with my care team?
  • • Are there any patterns of high arches, tripping, or hand weakness in my parents, siblings, or children?
  • • How do I feel about discussing my genetic diagnosis with my biological family members?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Impact of Customized and Sustained Physiotherapy in Charcot-Marie-Tooth Disease.

    Chitapure T, Jethwani D, Zubair Ahmed S, Panigrahy C

    Cureus 2021; (13(8)):e17201 doi:10.7759/cureus.17201.

    PMID: 34540429
  2. 2

    Mechanisms and treatment strategies of demyelinating and dysmyelinating Charcot-Marie-Tooth disease.

    Hertzog N, Jacob C

    Neural regeneration research 2023; (18(9)):1931-1939 doi:10.4103/1673-5374.367834.

    PMID: 36926710
  3. 3

    De novo PMP2 mutations in families with type 1 Charcot-Marie-Tooth disease.

    Motley WW, Palaima P, Yum SW, et al.

    Brain : a journal of neurology 2016; (139(Pt 6)):1649-56 doi:10.1093/brain/aww055.

    PMID: 27009151
  4. 4

    Novel Myelin Protein Zero Mutation in 3 Generations of Vermonters With Demyelinating Charcot-Marie-Tooth Disease.

    Lorance DK, Mandigo KA, Hehir MK

    Journal of clinical neuromuscular disease 2018; (19(3)):101-107 doi:10.1097/CND.0000000000000188.

    PMID: 29465609
  5. 5

    Clinical characterization and genetic analysis of Korean patients with X-linked Charcot-Marie-Tooth disease type 1.

    Hong YB, Park JM, Yu JS, et al.

    Journal of the peripheral nervous system : JPNS 2017; (22(3)):172-181 doi:10.1111/jns.12217.

    PMID: 28448691
  6. 6

    Mutational screening of the SH3TC2 gene in Greek patients with suspected demyelinating recessive Charcot-Marie-Tooth disease reveals a varied and unusual phenotypic spectrum.

    Kontogeorgiou Z, Nikolaou K, Kartanou C, et al.

    Journal of the peripheral nervous system : JPNS 2019; (24(1)):125-130 doi:10.1111/jns.12305.

    PMID: 30653784
  7. 7

    [Charcot-Marie-Tooth Disease: Historical Evolution and Present Understanding].

    Yano C, Takashima H

    Brain and nerve = Shinkei kenkyu no shinpo 2025; (77(11)):1176-1184 doi:10.11477/mf.188160960770111176.

    PMID: 41233175
  8. 8

    Recent Advances in Drosophila Models of Charcot-Marie-Tooth Disease.

    Kitani-Morii F, Noto YI

    International journal of molecular sciences 2020; (21(19)) doi:10.3390/ijms21197419.

    PMID: 33049996
  9. 9

    Generation of one induced pluripotent stem cell line JUCGRMi004-A from a Charcot-Marie-Tooth disease type 1A (CMT1A) patient with PMP22 duplication.

    Liu X, Ishikawa KI, Hattori N, Akamatsu W

    Stem cell research 2024; (77()):103401 doi:10.1016/j.scr.2024.103401.

    PMID: 38537501
  10. 10

    X-linked Charcot-Marie-Tooth Disease Presenting with Stuttering Stroke-like Symptoms.

    Hardy DI, Licht DJ, Vossough A, Kirschen MP

    Neuropediatrics 2019; (50(5)):304-307 doi:10.1055/s-0039-1692982.

    PMID: 31220874
  11. 11

    ALS5/SPG11/KIAA1840 mutations cause autosomal recessive axonal Charcot-Marie-Tooth disease.

    Montecchiani C, Pedace L, Lo Giudice T, et al.

    Brain : a journal of neurology 2016; (139(Pt 1)):73-85 doi:10.1093/brain/awv320.

    PMID: 26556829
  12. 12

    Mutations in C1orf194, encoding a calcium regulator, cause dominant Charcot-Marie-Tooth disease.

    Sun SC, Ma D, Li MY, et al.

    Brain : a journal of neurology 2019; (142(8)):2215-2229 doi:10.1093/brain/awz151.

    PMID: 31199454
  13. 13

    Genotype-phenotype characteristics and baseline natural history of heritable neuropathies caused by mutations in the MPZ gene.

    Sanmaneechai O, Feely S, Scherer SS, et al.

    Brain : a journal of neurology 2015; (138(Pt 11)):3180-92 doi:10.1093/brain/awv241.

    PMID: 26310628
  14. 14

    Unilateral oculomotor palsy in Charcot-Marie-Tooth disease 1A (CMT 1A).

    Posa A, Emmer A, Kornhuber ME

    Clinical neurology and neurosurgery 2017; (155()):20-21 doi:10.1016/j.clineuro.2017.02.004.

    PMID: 28214652
  15. 15

    Charcot-Marie-Tooth disease: from historical landmarks in Brazil to current care perspectives.

    Cavalcanti EBU, Leal RCC, Marques Junior W, Nascimento OJMD

    Arquivos de neuro-psiquiatria 2023; (81(10)):913-921 doi:10.1055/s-0043-1770348.

    PMID: 37611635
  16. 16

    Whole-exome sequencing identifies a heterozygous mutation in SLC12A6 associated with hereditary sensory and motor neuropathy.

    Shi J, Zhao F, Pang X, et al.

    Neuromuscular disorders : NMD 2021; (31(2)):149-157 doi:10.1016/j.nmd.2020.11.002.

    PMID: 33323309
  17. 17

    Affected Children of Healthy Parents: Multiple Pediatric Cases of Autosomal Recessive Charcot-Marie-Tooth Disease in a Pakistani Family.

    Nusrat K, Mahmood S, Raza M, et al.

    Cureus 2019; (11(4)):e4417 doi:10.7759/cureus.4417.

    PMID: 31245205
  18. 18

    Three novel mutations in a group of Chinese patients with X-linked Charcot-Marie-Tooth disease.

    Chen B, Niu S, Wang X, et al.

    Clinical neurology and neurosurgery 2019; (184()):105430 doi:10.1016/j.clineuro.2019.105430.

    PMID: 31323543
  19. 19

    A Family With X-Linked Charcot-Marie-Tooth Disease Type 1: A Case for Reclassifying a Variant of Uncertain Significance in GJB1and Review of the Literature.

    Chrisman C, Keshav R, Record CJ, et al.

    Journal of clinical neuromuscular disease 2025; (27(1)):9-13 doi:10.1097/CND.0000000000000534.

    PMID: 40901913
  20. 20

    Electrophysiological and radiological diagnosis of hereditary motor and sensory polyneuropathy.

    Al-Khlaiwi T, Meo I, Butt MA, Khan A

    Journal of family medicine and primary care 2024; (13(6)):2511-2515 doi:10.4103/jfmpc.jfmpc_1513_23.

    PMID: 39027825
  21. 21

    AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy.

    Kagiava A, Karaiskos C, Richter J, et al.

    Gene therapy 2021; (28(10-11)):659-675 doi:10.1038/s41434-021-00250-0.

    PMID: 33692503

This page explains the genetics and biology of Charcot-Marie-Tooth disease for educational purposes only. Always consult your neurologist or a genetic counselor to interpret your specific genetic test results and family risks.

Stay up to date

Get notified when new research about Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy is published.

No spam. Unsubscribe anytime.